Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
Background: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predic...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.698502/full |
id |
doaj-31fa99ed6bdd443990c875f0dab774dd |
---|---|
record_format |
Article |
spelling |
doaj-31fa99ed6bdd443990c875f0dab774dd2021-07-15T06:32:49ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-07-01810.3389/fmed.2021.698502698502Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated CirrhosisYue ZhangChenkai HuangYuan NieQi LiuNanxi XiaoLinxiang LiuXuan ZhuBackground: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predicts outcomes in patients with decompensated cirrhosis.Materials and Methods: A single-center, observational, prospective study with 345 decompensated cirrhosis patients was conducted in the Gastroenterology Department between January 2017 and December 2020. Their plasma samples were tested by enzyme-linked immunosorbent assay (ELISA) for sCD163 within 24 hours of admission. These patients were followed up at 28 days, 3 months and 6 months. The independent risk factors were identified with uni- and multivariate logistic regression analyses. We evaluated the predictive performance of the new scoring system (including sCD163) and the original scoring system.Results: The sCD163 level was significantly higher in non-surviving patients than in surviving patients. Positive associations were found between sCD163 levels and the Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD) and albumin-bilirubin (ALBI) scores. Logistic regression confirmed that sCD163 was an independent risk factor for 28-day, 3-month, and 6-month mortality. The areas under the receiver operating characteristic curves (AUROCs) of the use of sCD163 for the prediction of 28-day, 3-month, and 6-month mortality were relatively higher (AUROCs: 0.856; 0.823 and 0.811, respectively). The AUROCs of the new scores obtained by adding sCD163 to the original scoring systems (CTP + sCD163, MELD + sCD163 and ALBI + sCD163) showed that the new scoring systems had better predictive performance than the original scoring systems at all time points (P < 0.001).Conclusion: sCD163 is a prognostic predictor of short-term and long-term outcomes in decompensated cirrhosis patients. Accordingly, the addition of sCD163 to the original clinical scoring systems improved their prognostic performance.https://www.frontiersin.org/articles/10.3389/fmed.2021.698502/fulldecompensated cirrhosissoluble CD163prognosisCTP scoreMELD scoreALBI score |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yue Zhang Chenkai Huang Yuan Nie Qi Liu Nanxi Xiao Linxiang Liu Xuan Zhu |
spellingShingle |
Yue Zhang Chenkai Huang Yuan Nie Qi Liu Nanxi Xiao Linxiang Liu Xuan Zhu Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis Frontiers in Medicine decompensated cirrhosis soluble CD163 prognosis CTP score MELD score ALBI score |
author_facet |
Yue Zhang Chenkai Huang Yuan Nie Qi Liu Nanxi Xiao Linxiang Liu Xuan Zhu |
author_sort |
Yue Zhang |
title |
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis |
title_short |
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis |
title_full |
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis |
title_fullStr |
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis |
title_full_unstemmed |
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis |
title_sort |
soluble cd163 is a predictor of mortality in patients with decompensated cirrhosis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2021-07-01 |
description |
Background: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predicts outcomes in patients with decompensated cirrhosis.Materials and Methods: A single-center, observational, prospective study with 345 decompensated cirrhosis patients was conducted in the Gastroenterology Department between January 2017 and December 2020. Their plasma samples were tested by enzyme-linked immunosorbent assay (ELISA) for sCD163 within 24 hours of admission. These patients were followed up at 28 days, 3 months and 6 months. The independent risk factors were identified with uni- and multivariate logistic regression analyses. We evaluated the predictive performance of the new scoring system (including sCD163) and the original scoring system.Results: The sCD163 level was significantly higher in non-surviving patients than in surviving patients. Positive associations were found between sCD163 levels and the Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD) and albumin-bilirubin (ALBI) scores. Logistic regression confirmed that sCD163 was an independent risk factor for 28-day, 3-month, and 6-month mortality. The areas under the receiver operating characteristic curves (AUROCs) of the use of sCD163 for the prediction of 28-day, 3-month, and 6-month mortality were relatively higher (AUROCs: 0.856; 0.823 and 0.811, respectively). The AUROCs of the new scores obtained by adding sCD163 to the original scoring systems (CTP + sCD163, MELD + sCD163 and ALBI + sCD163) showed that the new scoring systems had better predictive performance than the original scoring systems at all time points (P < 0.001).Conclusion: sCD163 is a prognostic predictor of short-term and long-term outcomes in decompensated cirrhosis patients. Accordingly, the addition of sCD163 to the original clinical scoring systems improved their prognostic performance. |
topic |
decompensated cirrhosis soluble CD163 prognosis CTP score MELD score ALBI score |
url |
https://www.frontiersin.org/articles/10.3389/fmed.2021.698502/full |
work_keys_str_mv |
AT yuezhang solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT chenkaihuang solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT yuannie solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT qiliu solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT nanxixiao solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT linxiangliu solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis AT xuanzhu solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis |
_version_ |
1721301738996105216 |